GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval as the First Treatment for Hypereosinophilic Syndrome

 GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval as the First Treatment for Hypereosinophilic Syndrome

GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval as the First Treatment for Hypereosinophilic Syndrome

Shots:

  • The approval is based on pivotal P-III study assessing Nucala (300mg, SC, q4w) + SOC vs PBO + SOC in 108 patients aged ≥12yrs.with uncontrolled HES for 32 wks.
  • Results: The pivotal P-III study demonstrated 50% fewer patients experienced a HES flare 28% vs 56%). The approval follows a PR of data from a clinical development program that included positive results from a pivotal P-III study
  • Mepolizumab is a mAb targeting IL-5, it works by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils to normal levels & it is first approved in 2015 for severe eosinophilic asthma

Click here ­to­ read full press release/ article | Ref: GSK | Image: Outsourcing Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post